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Abstract
Background: A substantial body of literature has accumulated during the past 20 years showing the plasma
concentrations of 5-fluorouracil (5-FU) to correlate with clinical response and/or toxicity in colorectal cancer, and
head and neck cancer, but little information is available concerning effects on long-term survival. Here, Japanese
patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a
definitive 5-FU/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the association between prognosis and the
plasma concentration of 5-FU was evaluated.
Methods: Forty-nine patients with ESCC, who were treated with a definitive 5-FU/CDDP-based CRT, were enrolled.
A course consisted of the continuous infusion of 5-FU at 400 mg/m
2/day for days 1-5 and 8-12, the infusion of
CDDP at 40 mg/m
2/day on days 1 and 8, and the radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with
a second course repeated after a 2-week interval. Plasma concentrations of 5-FU were determined by high
performance liquid chromatography at 5:00 PM on days 3, 10, 38 and 45, and at 5:00 AM on days 4, 11, 39 and 46.
Results: The overall 5-year survival rate was 42.9%. Age (P = 0.020), body weight (P = 0.019), and disease stage (P
= 0.048) affected the survival, and the survival depended on the clinical response assessed at 1 month after the
treatment (P = 0.001). Higher plasma concentrations of 5-FU resulted in a better clinical response (P = 0.043), and
trended to prolong survival (P = 0.321).
Conclusions: The long-term survival after treatment with a definitive 5-FU/CDDP-based CRT possibly depends on
the plasma concentrations of 5-FU, and further clinical studies with a larger number of cases are needed to clarify
the relationship between them.
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Background
A clinical report published in 1999, the RTOG (Radia-
tion Therapy Oncology Group) 85-01 trial involving 134
patients with T1-3, N0-1 and M0 esophageal cancer, is
of great interest in terms of clinical outcome because it
demonstrated a 5-year survival rate of 26% [1-4]. This
treatment consists of a 96-hr-infusion of 5-fluorouracil
(5-FU) at a daily dose of 1,000 mg/m
2/day in weeks 1, 5,
8 and 11, infusion of cisplatin (CDDP) at 75 mg/m
2/day
on the first day of weeks 1, 5, 8 and 11, and concurrent
radiation at 50 Gy in 25 fractions over 5 weeks, without
pre- or post-surgical resection. Simultaneously in Japan,
another version was proposed by Ohtsu and his co-
workers for advanced metastatic esophageal squamous
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sion of 5-FU at 400 mg/m
2/day in weeks 1, 2, 6 and 7,
infusion of CDDP at 40 mg/m
2/day on the first day of
w e e k s1 ,2 ,6a n d7 ,a n dc o n c u r r e n tr a d i a t i o na t6 0G y
in 30 fractions over 8 weeks [5,6]. Two independent
clinical investigations have shown curative potential
using this regimen for unresectable ESCC with T4 or
M1a [5,6], and a long-term evaluation of efficacy and
toxicity with 139 patients resulted in a complete
response (CR) rate of 56%, along with a 5-year survival
rate of 29% [7-9]. Currently, a definitive 5-FU/CDDP-
based chemoradiotherapy (CRT) is recognized as one of
the most promising treatments for esophageal cancer,
but given the extensive inter-individual variation in clin-
ical outcome and severe late toxicities, future improve-
ments will likely require the dose-modification of these
regimens, incorporation of a novel anticancer drug,
pharmacokinetically guided administration of 5-FU or
CDDP, and identification of responders via patient
genetic profiling [10].
5-FU exerts its anticancer effects through inhibition of
thymidylate synthase and incorporation of its metabolites
into RNA and DNA, and has been used widely for the
treatment of solid tumors for nearly 50 years [11]. A sub-
stantial body of literature has accumulated over the past
20 years showing the plasma concentrations of 5-FU to
correlate with clinical response and/or toxicity in color-
ectal cancer, and head and neck cancer [12-21]. Although
the therapeutic drug monitoring has not been used for
chemotherapeutic agents [22,23], the accumulation of
data has encouraged us to apply this strategy in the case
of 5-FU [24,25]. There are only 2 reports in which plasma
concentrations of 5-FU has been shown to correlate with
long-term survival [16,18], but Gamelin and his co-work-
ers conducted a phase III, multicenter, randomized trial
in which pharmacokinetically guided administration of 5-
FU was compared with conventional dosing in patients
with metastatic colorectal cancer, and concluded that
individual dose adjustments of 5-FU resulted in an
improved objective response rate and fewer severe toxici-
ties, and in a trend toward a higher survival rate [21].
A series of studies has been performed to find a mar-
ker predictive of clinical response 1 month after or
severe toxicities during treatment with a definitive 5-
FU/CDDP-based CRT in Japanese patients with ESCC
[26-31]. Obviously, the final goal of cancer chemother-
apy is an improvement in long-term survival, not a
short-term clinical response, so parameters predicting
prognosis have been absolutely imperative. In this study,
patients with ESCC were followed up for 5 years after
treatment with a definitive 5-FU/CDDP-based CRT.
This is the first report on the effects of plasma concen-
trations of 5-FU on long-term survival in cases of eso-
phageal cancer.
Methods
Patients
Forty-nine ESCC patients were enrolled in this study
based on the following criteria: 1) ESCC treated with a
definitive 5-FU/CDDP-based chemoradiotherapy at
Kobe University Hospital, Japan, from October, 2003 to
June, 2006; 2) clinical stage T1 to T4, N0 or N1, and
M0 or M1a according to the International Union
Against Cancer tumor-node-metastasis (TNM) classifi-
cation; 3) age less than 85 years; 4) an Eastern Coopera-
tive Oncology Group performance status of 0 to 2; 5)
adequate bone marrow, renal, and hepatic function; 6)
no prior chemotherapy; 7) no severe medical complica-
tions; and 8) no other active malignancies (except early
cancer). The tumors were histologically confirmed to be
primary, and no patients with recurrence were included
in this study.
Protocol
The protocol is presented in Figure 1. A course con-
sisted of the continuous infusion of 5-FU at 400 mg/m
2/
day for days 1-5 and 8-12, the infusion of CDDP at 40
mg/m
2/day on days 1 and 8, and the radiation at 2 Gy/
day on days 1 to 5, 8 to 12, and 15 to 19, with a second
course repeated after a 2-week interval [5,6]. If disease
progression/recurrence was observed, either salvage sur-
gery, endoscopic treatment, or another regimen of che-
motherapy was scheduled. This study was conducted
with the authorization of the institutional review board
and followed the medical research council guidelines of
Kobe University. Written informed consent was
obtained from all participants prior to enrollment.
Determination of plasma concentrations of 5-FU
Aliquots (5 mL) of blood were collected into etylenedia-
minetetraacetic acid-treated tubes at 5:00 PM on days 3,
10, 38, and 45, and at 5:00 AM on days 4, 11, 39, and
46 [26-30]. The plasma concentrations of 5-FU were
determined by high-performance liquid chromatography
as described previously [26-30].
Clinical response
The clinical response was evaluated as reported pre-
viously [5-9]. Briefly, a complete response (CR) was
defined as the complete disappearance of all measurable
and assessable disease at the first evaluation, which was
performed 1 month after the completion of CRT to
determine whether the disease had progressed. The clin-
ical response was evaluated by endoscopy and chest and
abdominal computed tomography (CT) scans in each
course. A CR at the primary site was evaluated by endo-
scopic examination when all of the following criteria
were satisfied on observation of the entire esophagus: 1)
disappearance of the tumor lesion; 2) disappearance of
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Page 2 of 8ulceration (slough); and 3) absence of cancer cells in
biopsy specimens. If small nodes of 1 cm or less were
detected on CT scans, the recovery was defined as an
“uncertain CR” after confirmation of no progression for
at least 3 months. An “uncertain CR” w a si n c l u d e da sa
CR when calculating the CR rate. When these criteria
were not satisfied, a non-CR was assigned. The existence
of erosion, a granular protruded lesion, an ulcer scar,
and 1.2 w/v% iodine/glycerin-voiding lesions did not
prevent an evaluation of CR. The evaluations were per-
formed every month for the first 3 months, and when
the criteria for CR were not satisfied at 3 months, the
result was changed to non-CR. Follow-up evaluations
were performed thereafter every 3 months for 3 years by
endoscopy and CT scan. After 3 years, patients were
seen every 6 months. During the follow-up period, a
routine course of physical examinations and clinical
laboratory tests was performed to check the patient’s
health.
Severe acute toxicities
A definitive 5-FU/CDDP-based CRT is associated with
acute toxicities, predominantly leucopenia, stomatitis,
and cheilitis [5-9]. Toxicity was evaluated using criteria
defined by the Japan Clinical Oncology Group [32].
These criteria were based on the National Cancer Insti-
tute Common Toxicity Criteria. Toxicity was assessed
on a 2 to 3 day basis during the CRT and subsequent
hospitalization period and on every visit after the com-
pletion of CRT. Episodes of leucopenia, stomatitis, and
cheilitis during the first 2 courses and subsequent 2
weeks (until day 70) were recorded as acute toxicities
and those of grade 3 or more as severe acute toxicities.
Survival after treatment with a 5-FU/CDDP-based CRT
Survival time was defined as the time from treatment
initiation to death from any cause or to the last date of
confirmation of survival. Survival data were updated on
June 25, 2011.
Data analysis and statistics
All values reported are the mean ± standard deviation
(SD). The unpaired Student’s t-test/Welch’st e s to r
Mann-Whitney’s U test was used for two-group com-
parisons, and AVOVA was for multiple comparisons.
Fisher’s exact test was also used for the analysis of con-
tingency tables. The difference of overall survival curves
was analyzed by Log-rank test. P values of less than 0.05
(two tailed) were considered to be significant.
Results
Demographic/clinicopathologic characteristics and clini-
cal outcome of 49 Japanese ESCC patients are summar-
ized in Table 1. The 1-year, 2-year, and 5-year survival
rates were 71.4%, 57.1%, and 42.9%, respectively. The
patients who survived 5 years or more were older (P =
0.020) and heavier (P = 0.019) than those who lasted
less than 5 years. There was a significant difference in
disease stage between the 2 groups (P = 0.048). The CR
rate was 76.2% for the patients surviving 5 years or
2 22
2 weeks
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1st course
1st
cycle
43 50
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2Gy/day
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Figure 1 Protocol of a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy. One course of treatment consisted of protracted
venous infusions of 5-fluorouracil (400 mg/m
2/day for days 1-5 and 8-12) and cisplatin (40 mg/m
2/day on days 1 and 8), and radiation (2 Gy/day
on days 1-5, 8-12, and 15-19), with a second course (days 36-56) repeated after a 2-week interval.
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Page 3 of 8more, but only 25.0% for the others (P = 0.0005). No
differences were found in the frequency of episodes of
severe acute leucopenia, stomatitis, and cheilitis.
Figure 2 shows the association of clinical response
with overall survival after the treatment with a definitive
5-FU/CDDP-based CRT in 49 patients with ESCC. The
survival depended on the response, i.e., CR or non-CR
(P = 0.001, Log-rank test). The plasma concentrations of
5-FU in the patients with a survival time of 5 years or
more and with less than 5 years are indicated in Table
2. There was no difference of the 8-point average values
of plasma concentrations of 5-FU between the 2 groups
(P = 0.536), although the clinical response depended on;
0.124 ± 0.036 μg/mL for CR, 0.105 ± 0.030 μg/mL for
non-CR (P = 0.043). Figure 3 shows the association of
the 8-point average value with overall survival. The
patients were divided into 2 groups based on an overall
average of 0.114 μg/mL, and again the effect on overall
survival was not confirm (P = 0.321, Log-rank test). The
plasma concentrations of 5-FU in the patients with CR,
but a survival period of less than 5 years, are listed in
Table 3. The 8-point average of the concentrations
tended to be higher than other subgroups (P = 0.226).
Discussion
Originally, 5-FU was administered alone as a bolus, but
more recently, it is being administered with biomodulating
agents and/or through continuous infusion [11,33].
Because of the preclinical evidence that increased
exposure to 5-FU improves its cytotoxic activity and the
fact that 5-FU has a short half-life in plasma, continuous
infusion has been proposed to increase the percentage of
tumor cells exposed to 5-FU [33]. These regimens have
resulted in improvements in response rates with improved
safety profiles in clinical studies [33]. At present, one of
the most important factors complicating the clinical use of
5-FU is extensive inter- and/or intra-individual variability
in pharmacokinetics, when doses are calculated based on
body surface area [24,25]. There is a need to individualize
5-FU dosing, and the shift from a bolus to continuous
infusion has created better conditions for dose manage-
ment [24,25]. Given that the plasma concentration of, or
systemic exposure to, 5-FU has been shown to correlate
with the response rate or the rate of adverse effects in
patients with advanced colorectal cancer and head and
neck cancer [12-21], pharmacokinetically guided dose
adjustment has attracted attention [24,25].
To our knowledge, however, there are only 2 reports
in which plasma concentrations of 5-FU were proven to
correlate with long-term survival [16,18]. Milano et al.
examined patients with head and neck cancer [16], and
Di Paolo et al. studied patients with colorectal cancer
[18], and both found that the AUC values of 5-FU were
significantly correlated with survival. Recently, Gamelin
and his co-workers compared pharmacokinetically
guided administration of 5-FU with conventional dosing
in patients with metastatic colorectal cancer, and found
that individual dose adjustments of 5-FU resulted in an
Table 1 Demographic/clinicopathologic characteristics and clinical outcome after treatment with a definitive 5-
fluorouracil/cisplatin-based chemoradiotherapy in 49 Japanese patients with esophageal squamous cell carcinoma
Group Total Survival of 5 years or more Survival of less than 5 years P
a)
N4 9 2 1 2 8
1) Demographic/clinicopathologic
Age, yr 64.5 ± 7.4 (48 -78)
b) 67.3 ± 5.8 (60 -78) 62.4 ± 7.9 (48 -76) 0.020
Height, cm 163.5 ± 6.6 (150-180) 161.9 ± 6.1 (150-171) 164.8 ± 6.8 (152-180) 0.125
Weight, kg 56.1 ± 9.6 (33-79) 59.8 ± 9.5 (40-74) 53.3 ± 8.9 (33-79) 0.019
Male/Female 46/3 20/1 26/2 1.000
Performance status, 0/1/2/unknown 24/20/4/1 11/7/2/1 13/13/2/0 0.579
Differentiation, well/moderate/poor/unknown 7/28/8/6 4/11/3/3 3/17/5/3 0.817
T1/T2/T3/T4 16/6/15/12 10/2/7/2 6/4/8/10 0.099
N0/N1 22/27 13/8 9/19 0.048
M0/M1a
c) 41/8 20/1 21/7 0.115
Stage I/II/III/IV 12/10/19/8 7/7/6/1 5/3/13/7 0.048
2) Clinical outcome
Complete response 23 (46.9%) 16 (76.2%) 7 (25.0%) 0.0005
Grade 3/4 Leucopenia 21(42.9%) 9 (42.9%) 12 (42.9%) 1.000
Grade 3/4 Stomatitis 7 (14.3%) 4 (19.0%) 3 (10.7%) 0.443
Grade 3/4 Cheilitis 8 (16.3%) 4 (19.0%) 4 (14.3%) 0.710
a) Survival of 5 years or more vs. less than 5 years.
b) The values are the mean ± SD, with the range in parentheses.
c) Noncervical primary tumors with positive supraclavicular lymph nodes were defined as M1a.
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Page 4 of 8improved objective response rate, and in a trend toward
a higher survival rate [21].
In this study, we have followed up Japanese patients
with ESCC for 5 years after treatment with a definitive
5-FU/CDDP-based CRT. Age (P = 0.020), body weight
(P = 0.019), and disease stage (P = 0.048) affected the
long-term survival, and the survival depended on the
clinical response assessed at 1 month after the
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Figure 2 Association of clinical response with overall survival in Japanese patients with esophageal squamous cell carcinoma. Line:
patients with a complete response (CR, N = 23), dotted line: patients not with a complete response (non-CR, N = 26). The survival depended on
the response (P = 0.001, Log-rank test).
Table 2 Plasma concentrations of 5-fluorouracil (μg/mL) during a definitive 5-fluorouracil/cisplatin-based
chemoradiotherapy in 49 Japanese patients with esophageal squamous cell carcinoma
Group Total Survival of 5 years or more Survival of less than 5 years P
a)
N4 9 2 1 2 8
1st cycle/1st course Day 3, PM 5:00 0.109 ± 0.060 0.122 ± 0.080 0.100 ± 0.041 0.294
Day 4, AM 5:00 0.076 ± 0.040 0.088 ± 0.044 0.068 ± 0.036 0.097
2nd cycle/1st course Day 10, PM 5:00 0.150 ± 0.074 0.137 ± 0.071 0.158 ± 0.077 0.357
Day 11, AM 5:00 0.134 ± 0.047 0.132 ± 0.048 0.136 ± 0.047 0.798
1st cycle/2nd course Day 38, PM 5:00 0.102 ± 0.056 0.097 ± 0.067 0.105 ± 0.049 0.676
Day 39, AM 5:00 0.076 ± 0.041 0.077 ± 0.042 0.076 ± 0.042 0.897
2nd cycle/2nd course Day 45, PM 5:00 0.146 ± 0.080 0.158 ± 0.101 0.136 ± 0.059 0.364
Day 46, AM 5:00 0.119 ± 0.047 0.126 ± 0.036 0.114 ± 0.054 0.399
Average of 8 sampling points 0.114 ± 0.034 0.118 ± 0.036 0.112 ± 0.032 0.536
a) Survival of 5 years or more vs. less than 5 years.
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Page 5 of 8treatment, i.e., CR or non-CR (P = 0.001, Figure 2). The
clinical response was determined by the 8-point average
values of plasma concentrations of 5-FU; 0.124 ± 0.036
μg/mL for the patients with CR, and 0.105 ± 0.030 μg/
mL for those with non-CR (P = 0.043), and therefore
the survival must be associated with the concentrations.
However, the concentrations were not high enough to
affect long-term survival (P = 0.321, Figure 3). This is
presumably due to low number of patients (N = 49),
and further clinical studies with a larger number of
cases are needed to clarify the effect on long-term
survival.
A subgroup analysis suggested plasma concentrations
of 5-FU to be higher in the patients with CR, but a sur-
vival period of less than 5 years, but there was no statis-
tical significance (Table 3). Death from esophageal
cancer often occurs in non-CR cases or in recurrent
cases. However, the reports indicated severe late toxic
effects, such as myocardial infarction, pericardial effu-
sion, and pleural effusion, in patients after a definitive
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P=0.321
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Figure 3 Association of 8-point average of plasma concentrations of 5-fluorouracil with overall survival in Japanese patients with
esophageal squamous cell carcinoma. Line: patients with plasma concentrations of 5-FU of 0.114 μg/mL or more (N = 25), dotted line:
patients with plasma concentration of 5-FU of less than 0.114 μg/mL (N = 24). No statistical significant difference was observed (P = 0.321, Log-
rank test).
Table 3 Plasma concentrations of 5-fluorouracil (μg/mL) during a definitive 5-fluorouracil/cisplatin-based
chemoradiotherapy in the patients with a complete response, but survival of less than 5 years
Survival of 5 years or more Survival of less than 5 years
CR
a) Non-CR CR Non-CR P
b)
N1 6 5 7 2 1
Average of 8 sampling points 0.122 ± 0.031 0.105 ± 0.051 0.131 ± 0.046 0.105 ± 0.024 0.226
a) Complete response
b) Assessed by ANOVA
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Page 6 of 85-FU/CDDP-based CRT, especially in cases of extensive
radiation [8,9]. Here, 2-5 of 49 patients seemed to have
died from late toxicity. This might affect the association
of the plasma concentrations of 5-FU with long-term
survival.
Conclusions
Japanese ESCC patients were followed up for 5 years
after treatment with a definitive 5-FU/CDDP-based
CRT, and the association between prognosis and the
plasma concentration of 5-FU was evaluated. Age, body
weight, and disease stage affected the log-term survival,
and the survival depended on the clinical response
assessed at 1 month after the treatment. Higher plasma
concentrations of 5-FU resulted in a better clinical
response, and tended to prolong survival. Further clini-
cal studies with a larger number of cases are needed to
clarify the effect on long-term survival.
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